CTAD 2017 (Boston, USA | 1-4 Nov)

You are here: Home » CTAD 2017 (Boston, USA | 1-4 Nov)

Nov 4, 2017 dm (0)

Dr Mohammad Afshar (Ariana CEO) is presenting on the analysis of Phase 2a trial results using Ariana’s KEM® artificial intelligence platform at CTAD 2017 (10th Clinical Trials on Alzheimer’s Disease) in Boston, USA on 4 November.

LB18 – Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease
Mohammad Afshar, MD, PhD[1], Frédéric Parmentier, PhD[1], Ene I Ette, PhD[2], Emmanuel O Fadiran, PhD[3], Christopher U Missling, PhD[3]
[1]Ariana Pharma, Paris, France, [2]Anoixis Corp., Natick, MA, [3]Anavex Life Sciences Corp., New York, NY

Links: Download Press Release | Download Presentation